MDxHealth (MDXH) Corporate presentation summary

Growth fundamentals and strategy

• Expansion of clinical pathway for prostate cancer through acquisitions of Genomic Prostate Score and ExoDx Prostate Test.

• Comprehensive prostate cancer menu supported by robust clinical data and established reimbursement.

• Over 500,000 patients tested and expanding US commercial footprint with a team of over 80.

• Opportunities include menu expansion, decentralization, and channels outside urology.

Market opportunity and product portfolio

• Addressable US market opportunity estimated at $4.9B, with key products in prostate cancer and urinary tract infection.

• ExoDx Prostate Test, Confirm mdx, GPS mdx, and Resolve mdx form a comprehensive urology menu.

• Monitor mdx in development for active surveillance, targeting a $1.5B segment.

Clinical evidence and product differentiation

• ExoDx Prostate Test is non-invasive, independent of standard risk factors, and included in NCCN and AUA guidelines.

• Confirm mdx offers 96% NPV for aggressive prostate cancer, validated in over 55 studies, and included in EAU and NCCN guidelines.

• GPS mdx predicts adverse pathology and guides treatment, validated in over 20 studies and diverse populations.

• Resolve mdx improves UTI diagnosis, detects pathogens missed by traditional culture, and guides antibiotic selection.